In the Claims

Please amend the claims by replacing all prior versions, and listings, of claims pursuant to 37 C.F.R. §1.121(c) as follows:

1-15. (Canceled)

16. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective~~an~~ amount of a mixture of terpolymers, each terpolymer consisting of tyrosine, alanine and lysine~~effective to treat an autoimmune disease, and a pharmaceutically acceptable carrier, wherein each terpolymer consists of randomly polymerized tyrosine, alanine and lysine~~.

17-18. (Canceled)

19. (Previously Presented) The pharmaceutical composition of Claim 16, wherein said tyrosine is present in a mole fraction of about 0.005 to about 0.250; said alanine is present in a mole fraction of about 0.3 to about 0.6; and lysine is present in a mole fraction of about 0.1 to about 0.5.

20. (Previously Presented) The pharmaceutical composition of Claim 16, wherein said tyrosine is present in a mole fraction of 0.10, said alanine is present in a mole fraction of 0.54, and said lysine is present in a mole fraction of 0.35.

21-31. (Canceled)

32. (Previously Presented) The pharmaceutical composition of Claim 16 wherein said mixture of terpolymers has an average molecular weight of about 2,000 to about 40,000 daltons.

33. (Previously Presented) The pharmaceutical composition of Claim 16 wherein said mixture of terpolymers has an average molecular weight of about 4,000 to about 9,000 daltons.

34. (Currently Amended) The ~~pharmaceutical composition~~method of Claim ~~16~~157, wherein said autoimmune disease is a B cell mediated autoimmune disease.

35. (Currently Amended) The method~~pharmaceutical composition~~ of Claim ~~16~~157, wherein said autoimmune disease is a T cell mediated autoimmune disease.

36. (Currently Amended) The method~~pharmaceutical composition~~ of Claim ~~16~~157, wherein said autoimmune disease is an arthritic condition.

37. (Currently Amended) The method~~pharmaceutical composition~~ of Claim ~~16~~157, wherein said autoimmune disease is a demyelinating disease.

38. (Currently Amended) The method~~pharmaceutical composition~~ of Claim ~~16~~157, wherein said autoimmune disease is an inflammatory disease.

39-156. (Canceled)

157. (Withdrawn) A method for treating a subject afflicted with an autoimmune disease which comprises administering to the subject the pharmaceutical composition of claim 16.

158. (Withdrawn-Currently Amended) The method of claim 157, wherein the autoimmune disease is multiple sclerosis, autoimmune hemolytic anemia, autoimmune oophoritis, autoimmune thyroiditis, autoimmune uveoretinitis, Crone's disease, chronic immune thrombocytopenic purpura, colitis, contact sensitivity disease, diabetes mellitus, Graves disease, Guillain-Barre's syndrome, Hashimoto's disease, idiopathic myxedema, myasthenia gravis, psoriasis, pemphigus vulgaris, rheumatoid arthritis, or systemic lupus erythematosus.

159. (Withdrawn) The method of claim 158, wherein the autoimmune disease is multiple sclerosis.

160. (Withdrawn) The method of claim 158, wherein the autoimmune disease is rheumatoid arthritis.

161. (Withdrawn-Currently Amended) The method of claim 160, wherein the amount of the mixture of terpolymers is at least 5 mg/day.

162. (Withdrawn-Currently Amended) The method of claim 161, wherein the amount of the mixture of terpolymers is at least 10 mg/day.

163. (Withdrawn-Currently Amended) The method of claim 162, wherein the amount of the mixture of terpolymers is at least 15 mg/day.

164. (Withdrawn-Currently Amended) The method of claim 163, wherein the amount of the mixture of terpolymers is at least 20 mg/day.

165. (Withdrawn-Currently Amended) The method of claim 160, wherein the amount of the mixture of terpolymers is 25-400 µg/kg of the subject per day.